Activery The amorphization specialist
Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics
| Why creating a new amorphous drug combination |
 |
 |
 |
| Benefits of amorphous combinations: Currently, drug combinations are produced by mixing two or more compounds without considering any change in final solid state. The drug mixture is not considered an added value by itself. Conversely, Activery believes that the generation of stable amorphous drug combinations provides a new and innovative route to final dosage forms with differentiated pharmacokinetics. Having developed a new proprietary process (ASP - Atmospheric Supercritical Precipitation), Activery is now able to produce diverse amorphous drug mixtures in the micro- and nanometer range. Improved Bioavailability A change from a crystalline to an amorphous form enhances solubility and performance of these compounds. Extended Patent Protection Creating new and innovative solid state forms of pure APIs or their mixtures may strengthen new strategies for defense or entrance in mature markets. Non-crystalline states especially for mixtures are often unknown, thereby creating a unique window of opportunity for patent protection or generic market introduction. |
Pharma Notes
- New study on Inhaled Drug Delivery Market
- Particles that deliver larger and more effective doses of drugs to cancers
- The global protein therapeutics market will be worth $77bn by 2011 with biogenerics playing an increasingly important rol
- A federal jury in Texas Monday upheld the patent on Johnson & Johnson's arthritis treatment Remicade and ordered Abbott Laboratories to pay its rival $1.67 billion for infringing on the patent
- Transdermal delivery represents an attractive alternative to oral delivery of drugs and is poised to provide an alternative to hypodermic injection tool
Differentiated Generics
- Teva may lose patent challenge
- Labopharm receives notice of ANDA submission with paragraph IV certification for generic of Ryzolt
- Depomed (DEPO) Receives Paragraph IV Notice from Lupin Limited Over Patent Filing for Generic Glumetza Tablets
- The rate and number of successful Paragraph IV challenges is reducing the average effective patent life for innovator drugs
- Teva Sues Mylan Over Multiple Sclerosis Drug COPAXONE
Nanoparticles world
- Nanoparticle created to attack cardiovascular plaque
- Nanoparticle lung threat blocked
- Newly-developed nanoparticle to build therapies for treating individuals with cardiovascular disease.
- Nanoparticle Processing in the Solid State Dramatically Increases the Cell Membrane Permeation of a Cholesterol-Lowering Drug, Probucol
- Erectile dysfunction could be treated by a nanoparticle formulation applied directly to the penis